<p>根據 Causeway Capital Management LLC 最近向 SEC 提交的 Form 13F 文件，該公司在第三季度減少了對 Smith &amp; Nephew SNATS, Inc.（NYSE:SNN - 免費報告）股票的持股比例，降幅為 30.3%。該基金在此期間出售了 248,476 股後，持有 572,532 股該醫療設備提供商的股票。截至最近的 SEC 文件，Causeway Capital Management LLC 持有的 Smith &amp; Nephew SNATS 股票約佔 0.13%，價值 20,777,000 美元。</p>
<p>獲取 <strong>Smith &amp; Nephew SNATS</strong> 警報：</p>
<ul>
<li>聖誕節行情提前到來，影響這些股票</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也增加或減少了對 SNN 的持股。摩根大通在第二季度將對 Smith &amp; Nephew SNATS 的持股增加了 6,663.4%。摩根大通現在持有 1,210,655 股該醫療設備提供商的股票，價值 37,082,000 美元，此前在此期間又購買了 1,192,755 股。ABC Arbitrage SA 在第二季度將對 Smith &amp; Nephew SNATS 的持股增加了 1,063.4%。ABC Arbitrage SA 現在持有 898,635 股該醫療設備提供商的股票，價值 27,525,000 美元，此前在上個季度又購買了 821,393 股。Todd Asset Management LLC 在第三季度購買了 Smith &amp; Nephew SNATS 的新頭寸，估計價值約為 26,319,000 美元。高盛集團在第一季度將對 Smith &amp; Nephew SNATS 的持股增加了 49.2%。高盛集團現在持有 1,771,401 股該醫療設備提供商的股票，價值 50,255,000 美元，此前在上個季度又購買了 583,809 股。最後，法國巴黎銀行金融市場在第二季度將對 Smith &amp; Nephew SNATS 的持股增加了 365.1%。法國巴黎銀行金融市場現在持有 644,525 股該醫療設備提供商的股票，價值 19,742,000 美元，此前在上個季度又收購了 505,934 股。目前，25.64% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Smith &amp; Nephew SNATS 股價下跌 0.8%</h2>
<p>週二，SNN 股票開盤價為 34.03 美元。該股票的 50 日移動平均線為 34.45 美元，200 日移動平均線為 34.89 美元。Smith &amp; Nephew SNATS, Inc.的 52 周低點為 23.91 美元，52 周高點為 38.79 美元。該公司的速動比率為 1.25，流動比率為 2.57，債務與股本比率為 0.60。</p>
<h2>Smith &amp; Nephew SNATS 分紅公告</h2>
<ul>
<li>外科中心、醫療科技股票因手術需求積壓而上漲</li>
</ul>
<p>該公司最近宣佈了一項分紅，將於 5 月 27 日（星期三）支付。3 月 27 日（星期五）登記的投資者將獲得每股 0.482 美元的分紅。除息日期為 3 月 27 日（星期五）。這代表着 281.0% 的分紅收益率。</p>
<h2>華爾街分析師預測增長</h2>
<p>多位股票分析師對該股票發表了評論。Weiss Ratings 在 1 月 21 日（星期三）的研究報告中重新發布了對 Smith &amp; Nephew SNATS 的 “持有（c+）” 評級。Kepler Capital Markets 在 11 月 17 日（星期一）的研究報告中將 Smith &amp; Nephew SNATS 的評級提升至 “強力買入”。Wall Street Zen 在週六的研究報告中將 Smith &amp; Nephew SNATS 的評級從 “買入” 升級為 “強力買入”。Canaccord Genuity Group 在 3 月 5 日（星期四）的研究報告中將 Smith &amp; Nephew SNATS 的目標價從 34.00 美元提升至 35.00 美元，並給予該股票 “持有” 評級。最後，加拿大皇家銀行在 12 月 15 日（星期一）的報告中將 Smith &amp; Nephew SNATS 的評級從 “跑贏大盤” 下調至 “行業表現”。一位投資分析師對該股票給予了強力買入評級，五位分析師對該公司給予了持有評級。根據 MarketBeat 的數據，Smith &amp; Nephew SNATS 目前的平均評級為 “持有”，共識目標價為 36.25 美元。</p>
<ul>
<li>三隻醫療保健分紅股票，價格增長顯著</li>
</ul>
<p><strong>閲讀我們關於 Smith &amp; Nephew SNATS 的最新報告</strong></p>
<h2>Smith &amp; Nephew SNATS 公司簡介</h2>
<p>（免費報告）</p>
<p>Smith &amp; Nephew plc 是一家全球醫療技術公司，專注於先進外科設備、骨科重建植入物、創傷和四肢產品、運動醫學解決方案以及傷口護理療法的設計、開發和製造。該公司成立於 1856 年，總部位於英國赫爾，通過有機創新和戰略收購不斷發展，提供廣泛的產品組合，以滿足關節置換、微創手術和傷口癒合等患者需求。</p>
<p>在其骨科業務中，Smith &amp; Nephew 提供髖關節和膝關節置換系統、模塊化關節修復植入物以及骨修復的生物解決方案。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Smith &amp; Nephew SNATS</li>
<li>市場剛剛分裂為兩部分（緊急）</li>
<li>在 2026 年 5 月 15 日之前購買這隻黃金股票</li>
<li>摩根大通正在押注這種貨幣</li>
<li>中央銀行剛剛做了一件自 1967 年以來未曾做過的事情</li>
<li>股票代碼揭曉：預 IPO 獲取 “下一個埃隆·馬斯克” 公司的機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Smith &amp; Nephew SNATS 嗎？</h2>
<p>在考慮 Smith &amp; Nephew SNATS 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Smith &amp; Nephew SNATS 並不在名單上。</p>
<p>雖然 Smith &amp; Nephew SNATS 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>Causeway Capital Management LLC 將其在 Smith & Nephew SNATS, Inc. 的持股減少了 30.3%，在第三季度出售了 248,476 股，目前持有 572,532 股，價值 2080 萬美元。其他機構投資者，包括摩根大通和高盛，也顯著調整了他們的持倉。Smith & Nephew 的股票開盤價為 34.03 美元，52 周價格區間為 23.91 美元至 38.79 美元。該公司宣佈每股派息 0.482 美元，收益率為 281.0%。分析師的評級意見不一，平均共識為 “持有”，目標價為 36.25 美元</p>

<p>Causeway Capital Management LLC lessened its stake in shares of Smith &amp; Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 30.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 572,532 shares of the medical equipment provider's stock after selling 248,476 shares during the period. Causeway Capital Management LLC owned about 0.13% of Smith &amp; Nephew SNATS worth $20,777,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據 Causeway Capital Management LLC 最近向 SEC 提交的 Form 13F 文件，該公司在第三季度減少了對 Smith &amp; Nephew SNATS, Inc.（NYSE:SNN - 免費報告）股票的持股比例，降幅為 30.3%。該基金在此期間出售了 248,476 股後，持有 572,532 股該醫療設備提供商的股票。截至最近的 SEC 文件，Causeway Capital Management LLC 持有的 Smith &amp; Nephew SNATS 股票約佔 0.13%，價值 20,777,000 美元。</p>
</div><p>Get <strong>Smith &amp; Nephew SNATS</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Smith &amp; Nephew SNATS</strong> 警報：</p>
</div><ul>
<li>Santa Rally comes early for these stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>聖誕節行情提前到來，影響這些股票</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNN. JPMorgan Chase &amp; Co. raised its holdings in shares of Smith &amp; Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase &amp; Co. now owns 1,210,655 shares of the medical equipment provider's stock worth $37,082,000 after purchasing an additional 1,192,755 shares during the period. ABC Arbitrage SA lifted its holdings in Smith &amp; Nephew SNATS by 1,063.4% during the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider's stock worth $27,525,000 after purchasing an additional 821,393 shares in the last quarter. Todd Asset Management LLC purchased a new position in Smith &amp; Nephew SNATS during the third quarter valued at approximately $26,319,000. Goldman Sachs Group Inc. grew its position in shares of Smith &amp; Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock valued at $50,255,000 after purchasing an additional 583,809 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Smith &amp; Nephew SNATS by 365.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider's stock worth $19,742,000 after acquiring an additional 505,934 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也增加或減少了對 SNN 的持股。摩根大通在第二季度將對 Smith &amp; Nephew SNATS 的持股增加了 6,663.4%。摩根大通現在持有 1,210,655 股該醫療設備提供商的股票，價值 37,082,000 美元，此前在此期間又購買了 1,192,755 股。ABC Arbitrage SA 在第二季度將對 Smith &amp; Nephew SNATS 的持股增加了 1,063.4%。ABC Arbitrage SA 現在持有 898,635 股該醫療設備提供商的股票，價值 27,525,000 美元，此前在上個季度又購買了 821,393 股。Todd Asset Management LLC 在第三季度購買了 Smith &amp; Nephew SNATS 的新頭寸，估計價值約為 26,319,000 美元。高盛集團在第一季度將對 Smith &amp; Nephew SNATS 的持股增加了 49.2%。高盛集團現在持有 1,771,401 股該醫療設備提供商的股票，價值 50,255,000 美元，此前在上個季度又購買了 583,809 股。最後，法國巴黎銀行金融市場在第二季度將對 Smith &amp; Nephew SNATS 的持股增加了 365.1%。法國巴黎銀行金融市場現在持有 644,525 股該醫療設備提供商的股票，價值 19,742,000 美元，此前在上個季度又收購了 505,934 股。目前，25.64% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Smith &amp; Nephew SNATS Trading Down 0.8%</h2>
<div class="lb-trans"><h2>Smith &amp; Nephew SNATS 股價下跌 0.8%</h2>
</div><p>Shares of SNN stock opened at $34.03 on Tuesday. The stock has a fifty day moving average of $34.45 and a 200 day moving average of $34.89. Smith &amp; Nephew SNATS, Inc. has a 52 week low of $23.91 and a 52 week high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.</p>
<div class="lb-trans"><p>週二，SNN 股票開盤價為 34.03 美元。該股票的 50 日移動平均線為 34.45 美元，200 日移動平均線為 34.89 美元。Smith &amp; Nephew SNATS, Inc.的 52 周低點為 23.91 美元，52 周高點為 38.79 美元。該公司的速動比率為 1.25，流動比率為 2.57，債務與股本比率為 0.60。</p>
</div><h2>Smith &amp; Nephew SNATS Dividend Announcement</h2>
<div class="lb-trans"><h2>Smith &amp; Nephew SNATS 分紅公告</h2>
</div><ul>
<li>Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand</li>
</ul>
<div class="lb-trans"><ul>
<li>外科中心、醫療科技股票因手術需求積壓而上漲</li>
</ul>
</div><p>The business also recently declared a dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date is Friday, March 27th. This represents a dividend yield of 281.0%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項分紅，將於 5 月 27 日（星期三）支付。3 月 27 日（星期五）登記的投資者將獲得每股 0.482 美元的分紅。除息日期為 3 月 27 日（星期五）。這代表着 281.0% 的分紅收益率。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts have commented on the stock. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Smith &amp; Nephew SNATS in a research note on Wednesday, January 21st. Kepler Capital Markets raised Smith &amp; Nephew SNATS to a &#34;strong-buy&#34; rating in a research note on Monday, November 17th. Wall Street Zen upgraded Smith &amp; Nephew SNATS from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Canaccord Genuity Group lifted their price target on shares of Smith &amp; Nephew SNATS from $34.00 to $35.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada lowered shares of Smith &amp; Nephew SNATS from an &#34;outperform&#34; rating to a &#34;sector perform&#34; rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Smith &amp; Nephew SNATS currently has an average rating of &#34;Hold&#34; and a consensus price target of $36.25.</p>
<div class="lb-trans"><p>多位股票分析師對該股票發表了評論。Weiss Ratings 在 1 月 21 日（星期三）的研究報告中重新發布了對 Smith &amp; Nephew SNATS 的 “持有（c+）” 評級。Kepler Capital Markets 在 11 月 17 日（星期一）的研究報告中將 Smith &amp; Nephew SNATS 的評級提升至 “強力買入”。Wall Street Zen 在週六的研究報告中將 Smith &amp; Nephew SNATS 的評級從 “買入” 升級為 “強力買入”。Canaccord Genuity Group 在 3 月 5 日（星期四）的研究報告中將 Smith &amp; Nephew SNATS 的目標價從 34.00 美元提升至 35.00 美元，並給予該股票 “持有” 評級。最後，加拿大皇家銀行在 12 月 15 日（星期一）的報告中將 Smith &amp; Nephew SNATS 的評級從 “跑贏大盤” 下調至 “行業表現”。一位投資分析師對該股票給予了強力買入評級，五位分析師對該公司給予了持有評級。根據 MarketBeat 的數據，Smith &amp; Nephew SNATS 目前的平均評級為 “持有”，共識目標價為 36.25 美元。</p>
</div><ul>
<li>3 Healthcare Dividend Payers With Big Price Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻醫療保健分紅股票，價格增長顯著</li>
</ul>
</div><p><strong>Read Our Latest Report on Smith &amp; Nephew SNATS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Smith &amp; Nephew SNATS 的最新報告</strong></p>
</div><h2>Smith &amp; Nephew SNATS Profile</h2>
<div class="lb-trans"><h2>Smith &amp; Nephew SNATS 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Smith &amp; Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.</p>
<div class="lb-trans"><p>Smith &amp; Nephew plc 是一家全球醫療技術公司，專注於先進外科設備、骨科重建植入物、創傷和四肢產品、運動醫學解決方案以及傷口護理療法的設計、開發和製造。該公司成立於 1856 年，總部位於英國赫爾，通過有機創新和戰略收購不斷發展，提供廣泛的產品組合，以滿足關節置換、微創手術和傷口癒合等患者需求。</p>
</div><p>In its orthopaedics business, Smith &amp; Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.</p>
<div class="lb-trans"><p>在其骨科業務中，Smith &amp; Nephew 提供髖關節和膝關節置換系統、模塊化關節修復植入物以及骨修復的生物解決方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Smith &amp; Nephew SNATS</li>
<li>The Market Just Split in Two (URGENT)</li>
<li>Buy this Gold Stock Before May 15th, 2026</li>
<li>J.P. Morgan is betting on this coin</li>
<li>Central banks just did something they haven’t done since 1967</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Smith &amp; Nephew SNATS</li>
<li>市場剛剛分裂為兩部分（緊急）</li>
<li>在 2026 年 5 月 15 日之前購買這隻黃金股票</li>
<li>摩根大通正在押注這種貨幣</li>
<li>中央銀行剛剛做了一件自 1967 年以來未曾做過的事情</li>
<li>股票代碼揭曉：預 IPO 獲取 “下一個埃隆·馬斯克” 公司的機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SNN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Smith &amp; Nephew SNATS Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Smith &amp; Nephew SNATS 嗎？</h2>
</div><p>Before you consider Smith &amp; Nephew SNATS, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Smith &amp; Nephew SNATS 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith &amp; Nephew SNATS wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Smith &amp; Nephew SNATS 並不在名單上。</p>
</div><p>While Smith &amp; Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Smith &amp; Nephew SNATS 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Causeway Capital Management LLC 出售了 Smith and Nephew SNATS, Inc. $SNN 的 248,476 股股票